

Supplementary Material

Hofko M et al., Detection of carbapenemases by real-time PCR and melt-curve analysis on the BD MAXTM System

Supplementary Material and Methods

Characterization of isolates by the German National Reference Laboratory

Laboratories in Germany were asked to send isolates fulfilling the following criteria to the German National Reference Laboratory (NRL) for multidrug-resistant bacteria (Department of Medical Microbiology, Ruhr-University Bochum): (a) Enterobacteriaceae with elevated MICs for ertapenem ($\text{MIC} \geq 0.5 \text{ mg/l}$), meropenem or imipenem ($\text{MIC} \geq 2 \text{ mg/l}$) or decreased inhibition zone diameters ($\leq 22 \text{ mm}$ for imipenem or meropenem or $\leq 25 \text{ mm}$ for ertapenem) with the exception of *Proteus* spp., *Morganella morganii* and *Providencia* spp. with elevated MIC or decreased inhibition zone solely for imipenem and a meropenem MICs of $\leq 0.25 \text{ mg/l}$. (b) *Pseudomonas aeruginosa* with resistance to imipenem, meropenem and ceftazidime. (c) *Acinetobacter baumannii* with resistance to imipenem and meropenem. Several phenotypic tests were performed routinely: the modified Hodge Test (1), the combined disk test with EDTA (2) and the combined disk test with boronic acid (3, 4) (Enterobacteriaceae only). In addition, the following PCRs followed by sequencing were performed routinely: *bla_{KPC}* (5) (Enterobacteriaceae and *P. aeruginosa* only), *bla_{GES}* (6) (*P. aeruginosa* only), *bla_{OXA-48}* (7) (Enterobacteriaceae only), *bla_{OXA-23/-24/-58}* (8) (*Acinetobacter* spp. only), *bla_{VIM}* (2), *bla_{IMP}* (2) and *bla_{NDM}* (9). If the phenotypic tests suggested the presence of a carbapenemase further PCRs for rarely occurring carbapenemases were performed. If negative, a microbiological bioassay was performed similar as described previously (10).

Collections of isolates

Two different collections from the National Reference laboratory were investigated in our study. (i), 129 isolates were selected. 89 had defined carbapenemase resistance genes, 40 were negative for carbapenemases. The positive strains comprised the following carbapenemase genes (details in Table S2): *bla_{KPC}* type (n=12), *bla_{GES}* type (n=4), *bla_{NDM}* type (n=12), *bla_{VIM}* type (n=25), *bla_{IMP}* type (n=12), *bla_{OXA-48}* type (n=15), *bla_{OXA-23}* type (n=6) and other *bla_{OXA}* type (n=6), with 3 of 89 strains carrying two carbapenemase genes. 40 strains

had decreased carbapenem susceptibility due to non-carbapenemase based mechanisms such as ESBL, AmpC and/or decreased membrane permeability. (ii), In a second collection a total of 152 isolates sent to the NRL for analysis of decreased carbapenem susceptibility in an entire half-month period (Jan, 21st to Feb, 6th 2013) were analyzed in a blinded study setup. Isolates were tested at the NRL as described above and in parallel analyzed with the here described assay. The blinding was lifted only after completion of the investigation, compared to the NRL data and discrepant results were analyzed on new isolates once. 65/152 (42.8%) of the isolates harbored carbapenemase genes.

Table S1

Primers for the detection of carbapenemase resistance genes

target	primer	sequence (5'-3')	amplicon size [bp]	reference
16S rRNA	16S-fw 16S-rv	TGG AGC ATG TGG TTT AAT TCG A TGC GGG ACT TAA CCC AAC A	159	<i>In-house</i>
KPC	KPC-fw KPC-rv	ATG TCA CTG TAT CGC CGT CT TTT TCA GAG CCT TAC TGC CC	893	(11)
GES	GES-C GES-D	GTT TTG CAA TGT GCT CAA CG TGC CAT AGC AAT AGG CGT AG	371	(12)
IMP-1	IMP-1F IMP-1R	TGA GCA AGT TAT CTG TAT TC TTA GTT GCT TGG TTT TGA TG	740	(13)
IMP-2	IMP-2F IMP-2R	GGC AGT CGC CCT AAA ACA AA TAG TTA CTT GGC TGT GAT GG	737	(13)
VIM-1	VIM-1F VIM-1R	TTA TGG AGC AGC AAC CGA TGT CAA AAG TCC CGC TCC AAC GA	920	(13)
VIM-2	VIM-2F VIM-2R	AAA GTT ATG CCG CAC TCA CC TGC AAC TTC ATG TTA TGC CG	865	(13)
OXA-48(like)	OXA-48A OXA-48B	TTG GTG GCA TCG ATT ATC GG GAG CAC TTC TTT TGT GAT GGC	744	(7)
NDM	NDM-A NDM-B	TCG ATC CCA ACG GTG ATA TT TGG ATC AAG CAG GAG ATC AA	287	<i>In-house</i>
OXA-23(like)	OXA-23f OXA-23r	GAT CGG ATT GGA GAA CCA GA ATT TCT GAC CGC ATT TCC AT	501	(8)

Table S2

Assay performance for detection of different carbapenemases on a reference collection

carbapene-mase type	β-lactamase NRL result	No.	Species	melt temp. (Tm) in mastermix (1) or (2)	BD MAX result	comparison to NRL ¹	
						con-cordant	dis-cordant
KPC-type	KPC-2	5	klpn(3), esco(1), klox(1)	92.8-93.5 (1)	KPC	5	
	KPC-3	5	klpn(3), esco(1), klox(1)	92.2-93.6 (1)	KPC	5	
GES-type	GES-1	1	psae	89.3 (1)	GES	1	
	GES-5	1	psae	89.5 (1)	GES	1	
	GES-11	1	acba	89.8 (1)	GES	1	
	GES-20	1	psae	89.5 (1)	GES	1	
	NDM-type	NDM-1/-6	9	klpn(3), esco(3), encl(1), prmi(1), acba(1)	92.6-94.1 (2)	NDM	9
VIM-type	NDM-2	1	acba	92.6 (2)	NDM	1	
	NDM-3	1	esco	92.3 (2)	NDM	1	
	VIM-1	11	klpn(2), klox(2), sema(1), esco(1), cifr(1), encl(3), psae(1)	90.5-92.2 (2)	VIM-1	11	
	VIM-2	8	klpn(1), psae(6), klox(1)	90.5-92.2 (1)	VIM-2	8	
	VIM-4	1	encl	90.4 (2)	VIM-1	1	
	VIM-5	1	psae	90.5 (2)	VIM-1	1	
	VIM-19	1	klpn	90.1 (2)	VIM-1	1	
	VIM-28	1	psae	90.8 (2)	VIM-1	1	
	IMP-1	1	psae	84.7 (1)	IMP-1		
	IMP-2/-19	1	psae	84.9 (1)	IMP-2	1	
IMP-type	IMP-4/-28	1	encl			1	
	IMP-7	2	psae(2)			2	
	IMP-8/-24	3	psae(3)			3	
	IMP-13	1	sema			1	
	IMP-14	1	encl			1	
	IMP-15	1	psae	84.4 (1)	IMP-2	1	
	IMP-16	1	psae	85.3 (1)	IMP-2	1	
	OXA-type	14	esco(2), klpn(7), enae(1), cifr(1), sema(1), klox(1), encl(1)	86.2-88.8 (2)	OXA-48	14	
	OXA-162	3	cifr(1), esco(1), klpn(1)	86.2-86.3 (2)	OXA-48	3	
	OXA-181	2	esco(1), klpn(1)	86.7; 87.6 (2)	OXA-48	2	
multiple	OXA-204	1	klpn	86.5 (2)	OXA-48	1	
	OXA-23	6	acba(6)	84.2-85.0 (2)	OXA-23	6	
	KPC-2, VIM-1	1	klpn	92.9 (1); 90.4 (2)	KPC, VIM-1	1	
	KPC-2, VIM-26	1	klpn	93.1 (1); 90.2 (2)	KPC, VIM-1	1	
	NDM-1/-6, OXA-48	1	klpn	92.4 (2); 86.1 (2)	NDM, OXA-48	1	
	Total (positive strains)	89				81 (91.0%)	8 (9.0%)
No carbapenemase	negative	40			negative	40	0

acba, *Acinetobacter baumanii*; cifr, *Citrobacter freundii* enae, *Enterobacter aerogenes*; encl, *Enterobacter cloacae*; esco, *Escherichia coli*; klox, *Klebsiella oxytoca*; klpn, *Klebsiella pneumoniae*; prmi, *Proteus mirabilis*; psae, *Pseudomonas aeruginosa*; sema, *Serratia marcescens*

¹ 9 strains had to be tested twice due to mix-up or contamination.

References

1. **CLSI.** 2010. Performance Standards for Antimicrobial Susceptibility Testing: 20th Informational Supplement M100-S20. Wayne, PA, USA.
2. **Pitout JD, Gregson DB, Poirel L, McClure JA, Le P, Church DL.** 2005. Detection of *Pseudomonas aeruginosa* producing metallo-beta-lactamases in a large centralized laboratory. *J Clin Microbiol.* **43**:3129-3135.
3. **Pasteran F, Mendez T, Guerriero L, Rapoport M, Corso A.** 2009. Sensitive screening tests for suspected class A carbapenemase production in species of Enterobacteriaceae. *J Clin Microbiol.* **47**:1631-1639.
4. **Giske CG, Gezelius L, Samuelsen O, Warner M, Sundsfjord A, Woodford N.** 2011. A sensitive and specific phenotypic assay for detection of metallo-beta-lactamases and KPC in *Klebsiella pneumoniae* with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin. *Clin Microbiol Infect.* **17**:552-556.
5. **Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC.** 2001. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* **45**:1151-1161.
6. **Dallenne C, Da Costa A, Decre D, Favier C, Arlet G.** 2010. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. *J Antimicrob Chemother.* **65**:490-495.
7. **Poirel L, Heritier C, Tolun V, Nordmann P.** 2004. Emergence of oxacillinase-mediated resistance to imipenem in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* **48**:15-22.
8. **Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, Amyes SG, Livermore DM.** 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in *Acinetobacter* spp. *Int J Antimicrob Agents.* **27**:351-353.
9. **Kaase M, Szabados F, Pfennigwerth N, Anders A, Geis G, Pranada AB, Rossler S, Lang U, Gatermann SG.** 2014. Description of the metallo-beta-lactamase GIM-1 in *Acinetobacter pittii*. *J Antimicrob Chemother.* **69**:81-84.
10. **Marchiaro P, Mussi MA, Ballerini V, Pasteran F, Viale AM, Vila AJ, Limansky AS.** 2005. Sensitive EDTA-based microbiological assays for detection of metallo-{beta}-lactamases in nonfermentative gram-negative bacteria. *J Clin Microbiol.* **43**:5648-5652.
11. **Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, Rahal JJ, Brooks S, Cebular S, Quale J.** 2004. Emergence of carbapenem-resistant *Klebsiella* species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. *Clin Infect Dis.* **39**:55-60.
12. **Weldhagen GF, Prinsloo A.** 2004. Molecular detection of GES-2 extended spectrum Beta-lactamase producing *Pseudomonas aeruginosa* in Pretoria, South Africa. *Int J Antimicrob Agents.* **24**:35-38.
13. **Yan JJ, Hsueh PR, Ko WC, Luh KT, Tsai SH, Wu HM, Wu JJ.** 2001. Metallo-beta-lactamases in clinical *Pseudomonas* isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. *Antimicrob Agents Chemother.* **45**:2224-2228.